214 results on '"Shalabi, Haneen"'
Search Results
2. INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities
3. A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials
4. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.
5. Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
6. The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes
7. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR
8. Chimeric Antigen Receptor T-cell Therapy: Current Status and Clinical Outcomes in Pediatric Hematologic Malignancies
9. Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
10. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells
11. Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells
12. Diagnostic pitfalls in assessment of ferritin following CAR‐T‐cell therapy: Understanding the hook effect.
13. Weathering the storm when the end of the road is near: A qualitative analysis of supportive care needs during CAR T‐cell therapy in pediatrics.
14. CD22 CAR T-Cells Manufactured in Prodigy System and in Bag Culture Yield Equivalent Responses for B-ALL
15. Long-Term Follow up Post CAR T-Cell Therapy in Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia
16. Neuroimaging Findings during Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) - a CAR T Cell Neurotoxicity Imaging Virtual Archive (CARNIVAL) Study
17. Apheresis Product Characteristics Predict Response to CD22 CAR T-Cell Therapy in Pediatric and Young Adult Patients with B-ALL
18. Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure
19. Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients
20. Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy
21. Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation
22. Intrathecal hydrocortisone for treatment of children and young adults with CAR T‐cell immune‐effector cell‐associated neurotoxicity syndrome
23. INSPIRED Symposium Part 3: Prevention and Management of Pediatric CAR T Cell-Associated Emergent Toxicities
24. List of Contributors
25. Relapse Management and Role for Consolidative Hematopoietic Stem Cell Transplantation Following CAR T-Cell Therapy
26. Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome.
27. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
28. List of Contributors
29. Cell-Based Therapies
30. Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy
31. CD19 CAR T cells for infants and young children
32. Anakinra utilization in refractory pediatric CAR T-cell associated toxicities
33. CAR T-cells effective for post-CART relapse: A new treatment paradigm.
34. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
35. Efficacy of Second CAR-T (CART2) Infusion Limited by Poor CART Expansion
36. Immunotherapy Associated Neurotoxicity in Pediatric Oncology
37. Neurotoxicity following CD19/CD28ζ CAR T-cells in children and young adults with B-cell malignancies
38. Abstract PO-111: The impact of race, ethnicity and obesity on CAR T-cell outcomes
39. Case Report: Fatal Complications of BK Virus-Hemorrhagic Cystitis and Severe Cytokine Release Syndrome Following BK Virus-Specific T-Cells
40. Adverse Events Following CAR T-Cell Therapy: A Single Institution Retrospective Analysis of Toxicities Following CAR T-Cell Therapy for Children and Young Adults with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia
41. Faculty Opinions recommendation of Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study.
42. CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial
43. Consequences of hemophagocytic lymphohistiocytosis‐like cytokine release syndrome toxicities and concurrent bacteremia
44. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL
45. Chapter 10 - Relapse Management and Role for Consolidative Hematopoietic Stem Cell Transplantation Following CAR T-Cell Therapy
46. Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia
47. Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies
48. Abstract 4231: Factors predictive of CAR T cell associated hemophagocytic lymphohistiocytosis (HLH)
49. Abstract CT051: Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL
50. CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.